To view this email as a web page, click here

November 16, 2016

Subscribe

Our Team

Contact Us

FierceBiotech Logo

 

Today's Rundown

  1. Atlas, Third Rock join forces to launch new stem cell upstart

  2. Chinese scientists become first to test CRISPR in humans, as ‘Sputnik 2.0’ begins

  3. Bristol-Myers, Enterome pen microbiome I/O research pact

  4. CSL heart attack drug hits on safety, misses efficacy in PhIIb

  5. Rare disease biotech Glycomine raises $12M, with help from Chiesi venture arm

  6. Long-acting PCSK9 from Alnylam, TMC heads for PhIII, but safety spooks investors

  7. Amgen, Allergan step up to challenge Roche's Avastin with FDA biosim filing

  8. Novartis, Celgene and Pfizer trot out positive data in red-hot psoriatic arthritis race

  9. Livongo’s blood glucose meter is the first with downloadable updates

Featured Story

Atlas, Third Rock join forces to launch new stem cell upstart

For the first time, venture capital firms Atlas and Third Rock are coming together in a $48.5 million Series A to create and launch Magenta Therapeutics—a new biotech that aims to “reset and refresh the immune system.”


Top Stories

Chinese scientists become first to test CRISPR in humans, as ‘Sputnik 2.0’ begins

China has beaten out U.S. academics and biotechs to become the first in testing new gene editing tech known as CRISPR-Cas9 in humans.

Bristol-Myers, Enterome pen microbiome I/O research pact

Bristol-Myers Squibb has teamed with Enterome to discover microbiome-derived biomarkers, drug targets and bioactive molecules relevant to its immuno-oncology operation. The alliance positions Bristol-Myers to try to harness the potentially modulating effect of the gut microbiome on cancer immunotherapies.

CSL heart attack drug hits on safety, misses efficacy in PhIIb

A Phase IIb trial of CSL Behring’s post-heart attack protection candidate met its co-primary safety endpoints. The result, when paired to data supporting the mechanism of action, prompted CSL to start looking toward a Phase III trial, despite the drug failing to best placebo in a secondary efficacy endpoint.

Rare disease biotech Glycomine raises $12M, with help from Chiesi venture arm

In its Series A announced today Glycomine, an early-stage biotech working on replacement therapies for rare diseases, raised $12 million with help from Sanderling Ventures and Chiesi Ventures.

Long-acting PCSK9 from Alnylam, TMC heads for PhIII, but safety spooks investors

Positive mid-stage data has put The Medicines Company and partner Alnylam on course to start Phase III trials of a PCSK9-targeting drug that could be dosed just two or three times a year.

Amgen, Allergan step up to challenge Roche's Avastin with FDA biosim filing

Another day, another advancement for Roche’s biosimilar challengers—and this time, they’re coming after Avastin.

Novartis, Celgene and Pfizer trot out positive data in red-hot psoriatic arthritis race

Novartis’ Cosentyx and Celgene’s Otezla aren’t just battling it out in the psoriasis arena. As of early this year, they’re competing in psoriatic arthritis, too—and each drugmaker made its case this week with new data in that disease.

Livongo’s blood glucose meter is the first with downloadable updates

While we’re used to getting smartphone software updates wirelessly, the same couldn’t be said for blood glucose meters—until now. Livongo is rolling out its second-gen glucose meter with “over-the-air” capabilities, enabling users to receive updates on the go and manage their diabetes even better.

News of Note

New York-based oncology biotech BeyondSpring has filed with the SEC for a $100 million IPO. Story

Marina Biotech has closed a merger deal with IthenaPharma as the pair eye 2019 as the year for their first two launches. Release

Agilis Biotherapeutics says it has treated its first patient in a midstage test of its gene therapy for AADC deficiency, AGIL-AADC. Statement

Resources

[Infographic] Bridging the Patient ID Accuracy Gap

Get the stats you need to start down the path to a more secure infrastructure, today.

[Checklist] Customized Care Anywhere with Digital Signage

What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure.

[Whitepaper] The Paperless Future of Healthcare and Life Sciences

DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors.

[Whitepaper] DocuSign Life Sciences eBook: Reducing Cycle Time with Digital Transaction Management

The patients who rely on your scientific leadership are expecting more.

[Whitepaper] Streamline Regulatory Compliance in Life Sciences with Digital Transaction Management

The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company.

[Whitepaper] THE Rx FOR NEXT-GEN LIFE SCIENCES: How Technology Can Treat Industry Pain Points

Life sciences companies, like many industries today, face new challenges across the board. Read More.

[Research] Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics

Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report.

[Research] Biosimilars in the US Oncology Market (2nd Edition)

ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology.

[Research] Medical Science Liaisons in Oncology (2016)

Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information.

[Research] Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021

ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years.

[Research] Phase II/III CRO Quality Benchmarking

ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality.

[Whitepaper] Ensuring the Greatest Return From Your Poorly Soluble Molecule

Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more!

[Webinar] The Basics of Biotech 101, 201 & 301 - Price: $299

This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues.

[Whitepaper] Complimentary IDMP Report from Gartner

Gartner research on short- and long-term strategies for IDMP compliance.

Events

.